AR065721A1 - Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas. - Google Patents

Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.

Info

Publication number
AR065721A1
AR065721A1 ARP080101033A ARP080101033A AR065721A1 AR 065721 A1 AR065721 A1 AR 065721A1 AR P080101033 A ARP080101033 A AR P080101033A AR P080101033 A ARP080101033 A AR P080101033A AR 065721 A1 AR065721 A1 AR 065721A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
inhibitors
compounds
piridazinone
sintasa
Prior art date
Application number
ARP080101033A
Other languages
English (en)
Spanish (es)
Original Assignee
Albany Molecular Res Inc
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Res Inc, Schering Corp filed Critical Albany Molecular Res Inc
Publication of AR065721A1 publication Critical patent/AR065721A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP080101033A 2007-03-15 2008-03-13 Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas. AR065721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91817107P 2007-03-15 2007-03-15

Publications (1)

Publication Number Publication Date
AR065721A1 true AR065721A1 (es) 2009-06-24

Family

ID=39525788

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101033A AR065721A1 (es) 2007-03-15 2008-03-13 Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.

Country Status (18)

Country Link
US (1) US8232274B2 (enExample)
EP (2) EP2586778A3 (enExample)
JP (3) JP5147866B2 (enExample)
KR (1) KR20100049500A (enExample)
CN (1) CN101730692A (enExample)
AR (1) AR065721A1 (enExample)
AU (1) AU2008227100B2 (enExample)
BR (1) BRPI0809238A2 (enExample)
CA (1) CA2680583A1 (enExample)
CL (1) CL2008000725A1 (enExample)
CO (1) CO6220966A2 (enExample)
EC (1) ECSP099634A (enExample)
IL (1) IL200906A0 (enExample)
MX (1) MX2009009948A (enExample)
PE (1) PE20081882A1 (enExample)
RU (1) RU2009137946A (enExample)
TW (1) TW200902516A (enExample)
WO (1) WO2008115381A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2137162T3 (en) 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
EP2136808A2 (en) * 2007-03-15 2009-12-30 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
MX2010003117A (es) * 2007-09-20 2010-04-01 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2011313906B2 (en) * 2010-10-11 2015-08-13 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide CCR3 antagonists
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN103664795B (zh) * 2012-09-06 2017-10-03 华东理工大学 哒嗪酮类化合物及其用途
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014053973A2 (en) 2012-10-05 2014-04-10 Koninklijke Philips N.V. Medical imaging system and method for providing an enhanced x-ray image
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
WO2015031036A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN106456708A (zh) * 2014-04-24 2017-02-22 赫希玛有限公司 治疗的试剂和方法
EP3426029B1 (en) 2016-03-07 2023-08-30 AgroFresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
RU2019132396A (ru) * 2017-03-15 2021-04-15 Лунелла Байотек, Инк. Миторибосцины: терапевтические средства на основе митохондрий, направленные на раковые клетки, бактерии и патогенные дрожжи
BR112019020693B1 (pt) 2017-04-03 2023-11-28 Syngenta Participations Ag Compostos derivados de oxadiazol microbiocidas, suas composições, método para controlar ou prevenir a infestação de plantas úteis por microrganismos fitopatogênicos utilizando tais compostos e seus usos
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
CN109912476A (zh) * 2019-03-27 2019-06-21 南通宝凯化工有限公司 一种异丙氨基磺酰氯的生产工艺
WO2020253862A1 (zh) * 2019-06-21 2020-12-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
WO2021222353A1 (en) 2020-04-30 2021-11-04 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
WO2023204124A1 (ja) * 2022-04-20 2023-10-26 日本曹達株式会社 ピリダジノン化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS565734B2 (enExample) * 1973-02-28 1981-02-06
DE3048487A1 (de) * 1980-12-22 1982-07-29 Cassella Ag, 6000 Frankfurt Basisch substituierte pyridazine, ihre herstellung und ihre verwendung
ES540813A0 (es) 1985-02-28 1985-11-16 Abello Quimicos Farma Prod Sa Procedimiento de obtencion de 1,2-diazin-3 (2h)-onas con interes farmaceutico
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
GB2256587A (en) 1991-06-11 1992-12-16 American Cyanamid Co Acetazolamide in sustained release form
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
CN1633434A (zh) * 2002-01-31 2005-06-29 第一制药株式会社 咪唑并[1,2-a]吡啶衍生物
DE10216144A1 (de) * 2002-04-12 2003-11-06 Bayer Ag Substituierte 2-Phenyl-3(2H)-Pyridazinone
US20050209278A1 (en) * 2002-04-25 2005-09-22 Mcdonald Joseph J Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
JP4768628B2 (ja) * 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Mekの二環系阻害剤及びその使用方法
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
GB0524991D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
EP2136808A2 (en) * 2007-03-15 2009-12-30 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors

Also Published As

Publication number Publication date
AU2008227100A1 (en) 2008-09-25
CA2680583A1 (en) 2008-09-25
EP2137179B1 (en) 2015-09-02
CO6220966A2 (es) 2010-11-19
CN101730692A (zh) 2010-06-09
MX2009009948A (es) 2009-09-24
KR20100049500A (ko) 2010-05-12
US8232274B2 (en) 2012-07-31
JP2013014622A (ja) 2013-01-24
PE20081882A1 (es) 2008-12-27
ECSP099634A (es) 2009-10-30
EP2586778A3 (en) 2013-07-31
AU2008227100B2 (en) 2014-01-09
WO2008115381A1 (en) 2008-09-25
IL200906A0 (en) 2010-05-17
CL2008000725A1 (es) 2008-11-14
EP2586778A2 (en) 2013-05-01
JP5147866B2 (ja) 2013-02-20
JP2014051529A (ja) 2014-03-20
JP2010521461A (ja) 2010-06-24
BRPI0809238A2 (pt) 2014-09-09
TW200902516A (en) 2009-01-16
US20090170861A1 (en) 2009-07-02
EP2137179A1 (en) 2009-12-30
RU2009137946A (ru) 2011-04-20

Similar Documents

Publication Publication Date Title
AR065721A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
HN2010002733A (es) Compuestos y composiciones como inhibidores de cinasa
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BRPI1011838B8 (pt) compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
MX2010014041A (es) Una forma cristalina de posaconazol.
EA201170832A1 (ru) Пуриновые соединения
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
CR20110132A (es) Aminotriazolopiridinas y su uso como inhibidores de cinasa
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
CU23890B1 (es) Inhibidores heterocíclicos de estearoil-coa-desaturasa
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2011000195A1 (es) Compuestos derivados de 5-alquinil-pirimidina, inhibidores de quinasas; composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer.
PA8792401A1 (es) Fenilendiaminas
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal